Article info

Original research
Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression

Authors

  • Stefano Pierini Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USAOvarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Abhishek Mishra Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Renzo Perales-Linares Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Mireia Uribe-Herranz Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USAOvarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Silvia Beghi Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Andrea Giglio Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Sergei Pustylnikov Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Francesca Costabile Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Stavros Rafail Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Augusto Amici School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Marche, Italy PubMed articlesGoogle scholar articles
  • John G Facciponte Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Costantinos Koumenis Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Andrea Facciabene Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USAOvarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Andrea Facciabene; facciabe{at}pennmedicine.upenn.edu
View Full Text

Citation

Pierini S, Mishra A, Perales-Linares R, et al
Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression

Publication history

  • Accepted December 15, 2020
  • First published February 9, 2021.
Online issue publication 
February 09, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.